Utilization of care in haemophilia: A resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS)

Haemophilia, Supplement

Volumn 10, Issue 1, 2004, Pages 63-70

  Globe, Denize R ^a   Curtis, Randall G ^b   Koerper, Marion A ^c   Dietrich, Shelby ^d   Parish, Kathy ^d   Miller, Robert ^d   Sanders, Natalie ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Hugs Steering Committee ^*

Author keywords

Haemophilia A; Personnel; Resource based costs

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; DESMOPRESSIN; BLOOD CLOTTING FACTOR 8;

ACCESS TO INFORMATION; ADOLESCENT; ADULT; AGED; ARTHROPATHY; ARTICLE; CHILD; CLINICAL PRACTICE; COMORBIDITY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; EMERGENCY WARD; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE FINANCING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH STATUS; HEMOPHILIA A; HOSPITAL COST; HUMAN; INFORMATION PROCESSING; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL FEE; MEDICAL RECORD; PATIENT INFORMATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; COST OF ILLNESS; ECONOMICS; HEALTH CARE PLANNING; INFANT; MIDDLE AGED; NEWBORN; PHYSICIAN; PRESCHOOL CHILD; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; CALIFORNIA; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DRUG COSTS; FACTOR VIII; HEALTH CARE COSTS; HEALTH RESOURCES; HEMOPHILIA A; HOSPITAL COSTS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PHYSICIANS; RETROSPECTIVE STUDIES;

EID: 11044235064     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00849.x     Document Type: Article

References (18)

1. Salem-Schatz S, Moore G, Rucker M, Pearson SD. The case for case-mix adjustment in practice profiling. When good apples look bad. JAMA 1994; 272: 871-4.
2. Schnitzler MA, Woodward RS, Mundy LM, et al. Impact of risk adjustment estimators on ranking physician costs for pneumonia. Best Pract Benchmarking Healthc 1997; 2: 82-7.
3. Kerr E. Physicians Adopting Methods to Limit Utilization of Services. Los Angeles: UCLA Center for Health Policy Research Policy Brief, PB 96-2, 1996.
4. Globe DR, Cunningham WE, Anderson RM, et al. The Hemophilia Utilization Group Study: cost of out-patient, in-patient and pharmaceutical care. Int J Ped Hematol/Oncol 2001; 7: 87-100.
5. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24.
6. Chapko MK, Ehreth JL, Hedrick S. Methods of determining the cost of health care in the Department of Veterans Affairs medical centers and other nonpriced settings. Eval Health Prof 1991; 14: 282-303.
7. Smith PS, Teutsch SM, Shaffer PA, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
8. Morton SC, Kominski GF, Kahan JP. An examination of the Resource-Based Relative Value Scale cross-specialty linkage method. Med Care 1994; 32: 25-39.
9. Cardinale V, Chi J. Drug Topics Redbook: Medical Economics Montvale NJ: Medical Economics Data, 1996.
10. Office of Technology Assessment. Hip Fracture Outcomes in People Age 50 and Over: Mortality, Service Use, Expenditures, and Long-Term Functional Impairment. Washington, DC: US Department of Commerce, National Technical Information Service, 1993.
11. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277: 307-11.
12. Federal Register. Medicare Program: Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 1997 Rates: Proposed Rule. 1997; 62: 29 902-78.
13. Baker JR. Analysis of 1994 Region IX Hemophilia Program Patient Base from Comprehensive Care and HIV Risk Reduction Data Sets. Los Angeles: Children's Hospital, 1995.
14. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-64.
15. Globe DR, Cunningham WE, Anderson R, et al. Haemophilia Utilization Group Study: assessment of functional health status in haemophilia. Haemophilia 2002; 8: 121-8.
16. Globe DR, Cunningham WE, Anderson R, et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia 2003; 9: 325-31.
17. Anderson GF. In search of value: an international comparison of cost, access, and outcomes. Health Aff 1997; 16: 163-71.
18. Ross-Degnan D, Soumerai SB, Avorn J et al. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995; 11: 327-44.